Animal models for evaluating immune responses of human effector cells in vivo

Faisal Razzaqi, Wesley M. Burnside, Lolie Yu, Yan Cui

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Studying the responses of the human immune system to specific antigens in vivo for vaccine development has been limited by ethical and practical concerns. Up to now all of the in vivo preclinical testing for cancer vaccine development have been performed in various animal models. Although successful stimulation of antitumor immunity has been demonstrated by many therapeutic maneuvers in animal models, the outcome of subsequent clinical applications is less encouraging due to, at least in part, the limitations of currently used animal models, the most important of which is the inability to accurately mimic the human immune system in initiating and maintaining the immune responses. Therefore, an animal model that mimics or consists of crucial components of the functional human immune system will be valuable for vaccine development and testing. The first breakthrough came with the discovery of the severe combined immunodeficiency (SCID) mouse and its ability to sustain engrafted human cells, albeit at a low level. Since that discovery, several new strains of mice have been developed to improve human leukocyte, including stem cell, engraftment and their differentiation to functional human immune cells. The most recent models consist of mice with a mutation of the interleukin-2 receptor γ chain (IL2Rγc null) in the NOD/SCID background. This IL2Rγc null genotype led to mice with significantly decreased innate immunity that allows increased levels of human cell engraftment and multilineage development of human immune cells. With further improvements, these mouse models may help in the understanding of the complex human immune responses to cancers and infectious diseases and assist in preclinical evaluation of vaccine regimens.

Original languageEnglish (US)
Title of host publicationTargeted Cancer Immune Therapy
PublisherSpringer New York
Pages207-223
Number of pages17
ISBN (Print)9781441901699
DOIs
StatePublished - Dec 1 2009

Fingerprint

Animals
Animal Models
Immune system
Vaccines
Severe Combined Immunodeficiency
Immune System
Cells
Cancer Vaccines
Interleukin-2 Receptors
Testing
Stem cells
Aptitude
Human Development
Antigen-Antibody Complex
Innate Immunity
Communicable Diseases
Antigens
Immunity
Leukocytes
Stem Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Razzaqi, F., Burnside, W. M., Yu, L., & Cui, Y. (2009). Animal models for evaluating immune responses of human effector cells in vivo. In Targeted Cancer Immune Therapy (pp. 207-223). Springer New York. https://doi.org/10.1007/978-1-4419-0170-5_12

Animal models for evaluating immune responses of human effector cells in vivo. / Razzaqi, Faisal; Burnside, Wesley M.; Yu, Lolie; Cui, Yan.

Targeted Cancer Immune Therapy. Springer New York, 2009. p. 207-223.

Research output: Chapter in Book/Report/Conference proceedingChapter

Razzaqi, F, Burnside, WM, Yu, L & Cui, Y 2009, Animal models for evaluating immune responses of human effector cells in vivo. in Targeted Cancer Immune Therapy. Springer New York, pp. 207-223. https://doi.org/10.1007/978-1-4419-0170-5_12
Razzaqi F, Burnside WM, Yu L, Cui Y. Animal models for evaluating immune responses of human effector cells in vivo. In Targeted Cancer Immune Therapy. Springer New York. 2009. p. 207-223 https://doi.org/10.1007/978-1-4419-0170-5_12
Razzaqi, Faisal ; Burnside, Wesley M. ; Yu, Lolie ; Cui, Yan. / Animal models for evaluating immune responses of human effector cells in vivo. Targeted Cancer Immune Therapy. Springer New York, 2009. pp. 207-223
@inbook{59b6ae0574854c20b6e8a15b393423d5,
title = "Animal models for evaluating immune responses of human effector cells in vivo",
abstract = "Studying the responses of the human immune system to specific antigens in vivo for vaccine development has been limited by ethical and practical concerns. Up to now all of the in vivo preclinical testing for cancer vaccine development have been performed in various animal models. Although successful stimulation of antitumor immunity has been demonstrated by many therapeutic maneuvers in animal models, the outcome of subsequent clinical applications is less encouraging due to, at least in part, the limitations of currently used animal models, the most important of which is the inability to accurately mimic the human immune system in initiating and maintaining the immune responses. Therefore, an animal model that mimics or consists of crucial components of the functional human immune system will be valuable for vaccine development and testing. The first breakthrough came with the discovery of the severe combined immunodeficiency (SCID) mouse and its ability to sustain engrafted human cells, albeit at a low level. Since that discovery, several new strains of mice have been developed to improve human leukocyte, including stem cell, engraftment and their differentiation to functional human immune cells. The most recent models consist of mice with a mutation of the interleukin-2 receptor γ chain (IL2Rγc null) in the NOD/SCID background. This IL2Rγc null genotype led to mice with significantly decreased innate immunity that allows increased levels of human cell engraftment and multilineage development of human immune cells. With further improvements, these mouse models may help in the understanding of the complex human immune responses to cancers and infectious diseases and assist in preclinical evaluation of vaccine regimens.",
author = "Faisal Razzaqi and Burnside, {Wesley M.} and Lolie Yu and Yan Cui",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-1-4419-0170-5_12",
language = "English (US)",
isbn = "9781441901699",
pages = "207--223",
booktitle = "Targeted Cancer Immune Therapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - Animal models for evaluating immune responses of human effector cells in vivo

AU - Razzaqi, Faisal

AU - Burnside, Wesley M.

AU - Yu, Lolie

AU - Cui, Yan

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Studying the responses of the human immune system to specific antigens in vivo for vaccine development has been limited by ethical and practical concerns. Up to now all of the in vivo preclinical testing for cancer vaccine development have been performed in various animal models. Although successful stimulation of antitumor immunity has been demonstrated by many therapeutic maneuvers in animal models, the outcome of subsequent clinical applications is less encouraging due to, at least in part, the limitations of currently used animal models, the most important of which is the inability to accurately mimic the human immune system in initiating and maintaining the immune responses. Therefore, an animal model that mimics or consists of crucial components of the functional human immune system will be valuable for vaccine development and testing. The first breakthrough came with the discovery of the severe combined immunodeficiency (SCID) mouse and its ability to sustain engrafted human cells, albeit at a low level. Since that discovery, several new strains of mice have been developed to improve human leukocyte, including stem cell, engraftment and their differentiation to functional human immune cells. The most recent models consist of mice with a mutation of the interleukin-2 receptor γ chain (IL2Rγc null) in the NOD/SCID background. This IL2Rγc null genotype led to mice with significantly decreased innate immunity that allows increased levels of human cell engraftment and multilineage development of human immune cells. With further improvements, these mouse models may help in the understanding of the complex human immune responses to cancers and infectious diseases and assist in preclinical evaluation of vaccine regimens.

AB - Studying the responses of the human immune system to specific antigens in vivo for vaccine development has been limited by ethical and practical concerns. Up to now all of the in vivo preclinical testing for cancer vaccine development have been performed in various animal models. Although successful stimulation of antitumor immunity has been demonstrated by many therapeutic maneuvers in animal models, the outcome of subsequent clinical applications is less encouraging due to, at least in part, the limitations of currently used animal models, the most important of which is the inability to accurately mimic the human immune system in initiating and maintaining the immune responses. Therefore, an animal model that mimics or consists of crucial components of the functional human immune system will be valuable for vaccine development and testing. The first breakthrough came with the discovery of the severe combined immunodeficiency (SCID) mouse and its ability to sustain engrafted human cells, albeit at a low level. Since that discovery, several new strains of mice have been developed to improve human leukocyte, including stem cell, engraftment and their differentiation to functional human immune cells. The most recent models consist of mice with a mutation of the interleukin-2 receptor γ chain (IL2Rγc null) in the NOD/SCID background. This IL2Rγc null genotype led to mice with significantly decreased innate immunity that allows increased levels of human cell engraftment and multilineage development of human immune cells. With further improvements, these mouse models may help in the understanding of the complex human immune responses to cancers and infectious diseases and assist in preclinical evaluation of vaccine regimens.

UR - http://www.scopus.com/inward/record.url?scp=84900875962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900875962&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0170-5_12

DO - 10.1007/978-1-4419-0170-5_12

M3 - Chapter

AN - SCOPUS:84900875962

SN - 9781441901699

SP - 207

EP - 223

BT - Targeted Cancer Immune Therapy

PB - Springer New York

ER -